Abstract: Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded nucleic acid molecules shown in the first sequence and the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

Abstract: A detection panel for the universal detection of SARS-like coronaviruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation (“CDI”) detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.

Abstract: Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded protein molecules shown in the first sequence and, the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: A robust human cell culture model permissive to both SARS-COV-2 variants and MERS-COV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-COV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-COV-2 spike protein. By contrast, MERS-COV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549-ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 (“ACE2plusC3D4”) are highly susceptible to MERS-COV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

Abstract: A method, detection assay, and kit for rapidly detecting mutations of the SARS-COV-2 virus includes preparing a detection assay, performing an asymmetric real time-polymerase chain reaction (RT-PCR) on the detection assay using a Mic Real Time PCR cycler, and analyzing a melting curve to detect peaks at a 484 and a 501 codon of a gene, or detect peaks at a 452 codon and a 478 codon of a gene. The method, detection assay, and kit also provides for detecting of the SARS-COV-2 virus and mutations thereof. Disclosed is a high-throughput test that can detect multiple variants of the SARS-COV-2 virus within two-and-a-half hours, and is a major advance in tracking the virus and in treating patients. The test can detect UK, Brazil, South African, and Omicron variants, as well as others containing, for example, a key E484K mutation, which are gaining prominence as the virus evolves.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Aptamers having a G-quadruplex structure that bind specifically to the most commonly used azole-class antifungal drugs, biosensors that comprise those aptamers, and invitro methods for determining the level of one of those drugs utilizing those aptamers or biosensors.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: A detection panel for the universal detection of SARS-like coronaviruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation (“CDI”) detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.

Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.

Abstract: Aptamers having a G-quadruplex structure that bind specifically to the most commonly used azole-class antifungal drugs, biosensors that comprise those aptamers, and invitro methods for determining the level of one of those drugs utilizing those aptamers or biosensors.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.

Abstract: The disclosure relates to methods of treating a fungal infection in a subject by administering to the subject a salt of Compound 1, or a neutral form thereof. The methods of the disclosure can be useful in subjects suffering from treatment resistant infections, useful in subjects who have previously failed treatment with an anti-fungal therapy, and useful for suppressing the emergence of resistant strains in infected subjects.